Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513
- Registration Number
- NCT01000870
- Lead Sponsor
- Institute for Neurodegenerative Disorders
- Brief Summary
The purpose of the study is to evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers.
- Detailed Description
To determine diagnostic efficacy of the MNI-513 PET scans in differentiating between patients with probable AD and HVs on the basis of neocortical tracer binding pattern, the PET scans will be visually assessed by a nuclear physician experienced in the field of neuro-imaging. PET scan findings will be classified either as abnormal (i.e., significant neocortical uptake in predefined regions) or as normal (i.e. no significant neocortical uptake in predefined regions). The nuclear physician will be unaware of the clinical diagnosis.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 6
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Access MNI-513 and PET Imaging MNI-513-01 -
- Primary Outcome Measures
Name Time Method To evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Institute for Neurodegenerative Disorders
🇺🇸New Haven, Connecticut, United States